Author: Fiona Craig

Optima Health (LSE:OPT) reported unaudited revenue of approximately £121 million for the year ended 31 March 2026, representing growth of 15% and meeting market expectations. The company also indicated that adjusted EBITDA is expected to be around 10% ahead of previous forecasts, reflecting continued operational progress during the year.

Despite reporting net debt of £94.4 million, management highlighted the strength of the group’s balance sheet, supported by a recent equity fundraising that enabled the repayment of a £30 million bridging facility used to support acquisition activity.

Transformational PAM Acquisition Expands Market Position

A major milestone during the year was the completion of the £100 million acquisition of PAM Healthcare Limited, one of the largest occupational health and wellbeing providers in the UK and Ireland. The transaction significantly increases Optima Health’s scale and broadens its service offering across occupational health, wellbeing and clinical support services.

Management believes the acquisition strengthens the company’s position within a growing market while providing additional opportunities to enhance service delivery and expand its client base.

Integration Progressing Ahead of Expectations

The integration of PAM Healthcare is continuing in line with management’s plans, with annualised cost synergies of £1.3 million already achieved. The company expects further benefits to emerge as operations are combined and efficiencies are realised across the enlarged group.

Optima Health has reiterated its medium-term objectives of generating £200 million in annual revenue and £40 million in adjusted EBITDA, reflecting confidence in the enlarged business and its future growth prospects.

Focused on Growth and Market Share Expansion

Management remains focused on leveraging the combined capabilities of Optima Health and PAM to increase market share and strengthen its leadership position within occupational health and wellbeing services. The company believes its scale, clinical expertise and technology-led approach provide a strong platform for further expansion.

Market Considerations

The company’s outlook continues to be influenced by weaker cash generation, including negative free cash flow reported in 2025, alongside a relatively demanding valuation with a price-to-earnings ratio of around 50. Financial performance has improved through a return to profitability and manageable leverage levels, although earnings volatility remains a consideration. Technical indicators are mixed, with neutral momentum and the share price trading below longer-term trend averages.

More About Optima Health PLC

Optima Health PLC is a leading provider of occupational health and wellbeing services across the UK and Ireland. The company delivers clinically led and technology-enabled solutions to public and private sector organisations, helping employers improve workforce health, wellbeing and productivity.

The group employs more than 1,600 people, including around 800 clinicians, and operates a nationwide network of more than 50 clinics. Through Optima Health Ireland, the company also provides occupational health services throughout Ireland.

SThree (LSE:STEM) has reaffirmed its FY26 guidance after reporting first-half net fees of £147.7 million, down 7% year-on-year. Both contract and permanent recruitment activity remained below prior-year levels, although management noted that the pace of decline moderated during the period, supported by strong performances in the United States and Japan.

The company highlighted continued resilience in its contractor base, with extension rates remaining solid and its contractor order book increasing by 3%, providing approximately five months of revenue visibility.

Cost Controls Help Offset Market Weakness

Management said ongoing cost-efficiency initiatives are helping to mitigate softer demand across several European markets and technology-focused sectors. As a result, SThree continues to expect profit before tax of around £10 million for FY26.

The company believes its focus on operational discipline and workforce productivity is helping it navigate a challenging recruitment environment while preserving flexibility for future growth opportunities.

Technology Investments Supporting Productivity

SThree reported benefits from its Technology Improvement Programme introduced last year, which has contributed to productivity gains across the business. The programme is also enabling the development of AI-driven tools and more sophisticated workforce solutions for clients seeking comprehensive STEM talent services.

Management sees technology as an increasingly important differentiator, allowing the company to improve efficiency while delivering broader recruitment and workforce management capabilities.

Strong Balance Sheet Provides Flexibility

The group ended the period with net cash of £43 million, providing significant financial strength despite ongoing market uncertainty. SThree is also continuing its share buyback programme, which has a total value of up to £20 million.

Improving new business activity and stable contract performance have given management confidence that the company is well positioned to benefit from any recovery in hiring markets as economic conditions improve.

Market Considerations

The company’s outlook is supported by resilient cash generation and a healthy balance sheet, although recent declines in revenue and margin performance remain a headwind. Technical indicators are moderately constructive, with momentum continuing to improve despite the shares remaining slightly below their longer-term trend levels. Valuation metrics are comparatively supportive, reflecting a reasonable earnings multiple and an attractive dividend yield.

More About SThree plc

SThree plc is a specialist global STEM workforce consultancy focused on placing highly skilled professionals across science, technology, engineering and mathematics disciplines. The company operates in both contract and permanent recruitment markets, serving sectors including technology, engineering, life sciences and energy.

Its key geographic markets include the United States, Germany, the Netherlands, the United Kingdom and Japan, where it provides talent solutions to businesses seeking specialist technical expertise.

Everyman Media Group (LSE:EMAN) is evaluating a potential delisting from AIM as the premium cinema operator continues to deliver strong trading performance and expand its presence within the UK leisure sector. The company operates a portfolio of 49 cinemas designed to offer a premium entertainment experience, combining curated film programmes with hospitality-led service, food and drink offerings, and high-quality venue environments.

The business continues to position itself as an alternative to traditional multiplex operators by focusing on experience-led cinema visits and community-focused entertainment destinations.

Board Reviews Potential AIM Delisting

The company has confirmed that its board is assessing the merits of a possible withdrawal from AIM. The review follows indications of support from significant director shareholders, who collectively hold 45.6% of the company’s issued share capital. In addition, other investors representing at least 11% of the share register are understood to be supportive of such a move.

Any proposal to delist would remain subject to shareholder approval and further consultation with investors before a final decision is made.

Strong Operational Performance Continues

Trading during the 21 weeks to 28 May 2026 was robust, with admissions increasing by 23.1% and revenue rising 26.5% compared with the prior period. Adjusted EBITDA advanced 45.2%, reflecting both higher customer volumes and operational leverage across the estate.

The company also increased its market share to 6.7% while reducing net debt, demonstrating continued progress in strengthening its financial position. Management believes the business is benefiting from consumer demand for premium leisure experiences and the differentiated nature of the Everyman brand.

Outlook Supported by Growth but Challenges Remain

While current trading trends remain encouraging, management has highlighted several factors that could influence full-year performance, including broader economic uncertainty, the importance of the fourth quarter trading period and the impact of planned second-half investment projects.

As a result, the company expects full-year results to be only modestly ahead of those achieved in 2025, despite the strong start to the year.

Market Considerations

The company’s outlook continues to be affected by concerns over historical losses, elevated leverage levels and declining equity, while valuation metrics remain challenged by the absence of profitability and dividend payments. Technical indicators offer some support, with the shares maintaining an established upward trend and positive momentum signals. However, overbought conditions suggest the potential for increased short-term volatility.

More About Everyman Media Group

Everyman Media Group is a leading UK cinema operator focused on delivering premium entertainment experiences. The company operates 49 venues and 171 screens across the UK, combining mainstream and independent film programming with in-house food and beverage service in design-led venues.

Its cinemas are positioned as social and community destinations, offering customers an experience-focused alternative to conventional cinema formats.

TPXimpact Holdings (LSE:TPX) has reported unaudited FY26 results that highlight a significant improvement in profitability and financial strength, marking the completion of its three-year transformation programme. Revenue increased 1% to £78.1 million, while gross margin improved to 31.6% and adjusted EBITDA rose 54% to £8.6 million.

The company also returned to an operating profit after reporting a loss in the prior period. Net debt was reduced by half to £4.2 million, with leverage falling to 0.5 times, reflecting stronger cash generation and a more disciplined operating model.

Business Simplification Drives Performance

As part of its turnaround strategy, TPXimpact streamlined its organisational structure by combining nine business divisions into three core operating units. Management believes the simplified structure has created a more agile business capable of generating stronger margins and improved cash flow.

The reorganisation was designed to enhance operational efficiency while positioning the company to pursue larger and more strategic opportunities across its key markets.

Public Sector Demand Supports Growth

During the year, TPXimpact secured £122 million of new work, with the majority coming from public sector organisations across the UK. The company won several significant multi-year contracts with government bodies including DEFRA, NHS England and HM Land Registry.

Momentum has continued into the new financial year, with £31 million of orders already secured for FY27. Management expects this pipeline, combined with continued demand for digital transformation services, to support double-digit growth and further margin expansion in the years ahead.

Positioned for Long-Term Government Transformation Projects

TPXimpact believes its expertise in digital transformation, data, technology and organisational change positions it well to benefit from ongoing investment in modernising public services. The company continues to focus on building long-term client relationships and delivering programmes that improve efficiency, accessibility and service outcomes across government and healthcare.

Market Considerations

The company’s outlook continues to be influenced by concerns around historical losses, modest revenue growth and weaker free cash flow performance. However, positive technical indicators, including a share price trading above major moving averages, provide a degree of support. Valuation metrics remain challenging due to the company’s recent loss-making history and the absence of dividend data.

More About TPXimpact Holdings PLC

TPXimpact Holdings PLC is a UK-listed digital transformation specialist that works primarily with public sector and healthcare organisations. The group helps clients modernise services through technology, data, design and organisational change programmes, with expertise spanning central government, healthcare, justice and land management.

The company is increasingly integrating AI-enabled solutions into its offering while supporting clients in developing long-term digital capabilities and improving public service delivery.

Inspiration Healthcare (LSE:IHC) reported a robust performance for FY26, with revenue increasing 24% to £47.5 million, supported by strong demand for its SLE neonatal ventilation products. Sales of SLE products climbed 56% during the year, helping to improve gross margins and drive adjusted EBITDA to £2.8 million.

The group also strengthened its balance sheet through tighter working capital management, generating £7.5 million in operating cash flow and reducing net debt by 39% to £5.1 million. Operational improvements boosted manufacturing efficiency and contributed to a one-third reduction in inventory levels.

Strong Trading Supported by Key Contracts

During the year, Inspiration Healthcare completed a significant one-off export contract worth £9.5 million and delivered 10% underlying growth across the SLE business. The company also secured a multi-year purchasing agreement for its Airon division with a major U.S. healthcare provider, further expanding its presence in a key market.

Management highlighted the benefits of ongoing operational improvements, which have increased production capacity while supporting better inventory control and cash generation.

Strategic Shift Towards Core Neonatal Technologies

Following the year-end, the company agreed to transfer its infusion business to Micrel, a move designed to increase focus on its higher-priority neonatal technology operations. The disposal is expected to streamline the business and allow management to concentrate resources on areas with stronger long-term growth potential.

Despite the planned exit from lower-margin infusion distribution activities, the board expressed confidence in achieving market expectations for FY27 and remains optimistic about prospects heading into FY28.

Focused Platform for Future Growth

The company believes its combination of neonatal ventilation expertise, international distribution capabilities and growing U.S. presence provides a solid foundation for future expansion. Management expects continued investment in core technologies and operational efficiency to support further growth and profitability improvements.

Market Considerations

The company’s outlook continues to be influenced by concerns around financial performance, including historical losses, margin pressure, leverage and cash flow challenges. However, positive technical indicators, including a strong share price trend and favourable momentum signals, provide some support. Valuation remains constrained by negative earnings metrics and the absence of a positive price-to-earnings ratio.

More About Inspiration Healthcare

Inspiration Healthcare Group is a UK-based medical technology company focused on products used in neonatal intensive care. Its portfolio includes neonatal ventilators, respiratory support systems and single-use medical consumables designed to support premature and critically ill newborns.

The company markets both proprietary and distributed products directly to healthcare providers in the UK and Ireland, while also serving international markets through a distributor network spanning more than 75 countries. Its operations include SLE, a specialist in neonatal ventilation; Airon, a U.S.-based pneumatic ventilation business; and its UK and Ireland medical technology distribution division.

Gelion (LSE:GELN) has entered into an exclusive worldwide commercial licensing agreement with Max-Planck-Innovation GmbH covering nano-encapsulated sulfur cathode technology and advanced nano-confined anode materials. The agreement brings together both existing and future intellectual property generated through Gelion’s collaboration with the Max Planck Institute of Colloids and Interfaces.

Structured around milestone payments and royalty arrangements, the deal strengthens Gelion’s intellectual property portfolio and provides greater certainty as the company advances its sulfur battery technologies towards commercial deployment.

Strengthened Intellectual Property Platform

The licence gives Gelion exclusive access to key technologies that underpin recent advances in sulfur battery performance, including improvements in energy density, power delivery, operating temperature range and cycle life.

Management believes the agreement reduces commercialisation risk by securing long-term rights to critical innovations while creating a clearer route for integrating these developments into the company’s next-generation battery products. The strengthened IP position is also expected to support discussions with industrial partners and future commercial opportunities.

Accelerating the Path to Market

By securing exclusive rights to the technology, Gelion aims to move more rapidly from research and development into commercial execution. The company believes the agreement will help accelerate customer qualification programmes and collaboration efforts with Tier One industrial partners seeking advanced energy storage solutions.

The long-term access to breakthrough sulfur chemistry is expected to support the rollout of Gelion’s NES™ materials platform and enhance its ability to compete within fast-growing sustainable energy storage markets.

Building a Commercial Framework for Growth

The company views the agreement as an important step in transforming its scientific progress into scalable commercial products. As demand for advanced battery technologies increases across electric mobility, aviation and grid storage applications, Gelion believes its sulfur-based technologies offer a differentiated solution capable of leveraging existing battery manufacturing infrastructure.

Market Considerations

Gelion’s outlook continues to be influenced by ongoing losses, cash burn and a valuation profile constrained by negative earnings. However, these factors are partially offset by improving technical indicators, including a share price trading above key moving averages and positive momentum signals. Recent corporate updates have also highlighted progress on both technical and commercial milestones, alongside an improved EBITDA loss position, although execution and timing risks remain.

More About Gelion PLC

Gelion plc is a battery technology company focused on developing sulfur-based energy storage solutions for the clean energy transition. Its flagship Nano-Encapsulated Sulfur (NES™) technology is designed as a drop-in cathode material for lithium-sulfur and sodium-sulfur batteries, enabling compatibility with existing gigafactory infrastructure. The technology is being developed for applications including electric vehicles, e-aviation and large-scale grid energy storage.

Galileo Resources (LSE:GLR) has entered into an agreement to sell its wholly owned subsidiary, Virgo Business Solutions, to Metal Capital, a subsidiary of Sandfire Resources. Virgo holds two prospecting licences within Botswana’s Kalahari Copper Belt, and the transaction will deliver an upfront cash payment of US$3 million to Galileo.

The company intends to use the proceeds to support the advancement of its key projects in Zambia and Zimbabwe, reflecting its strategy of concentrating both capital and management attention on its core exploration regions.

Transaction Retains Significant Exploration Upside

In addition to the initial consideration, the agreement includes a contingent success payment ranging from US$20 million to US$80 million. The additional payment would become payable if future exploration activities result in the definition of a qualifying ore reserve containing at least 400,000 tonnes of copper.

While no mineral resource has yet been established on the licences and the contingent payment is not guaranteed, the structure allows Galileo to maintain exposure to the potential value of any major discovery without committing further exploration capital.

Major Exploration Commitment From Buyer

As part of the transaction, Metal Capital has committed to spend US$4.5 million on exploration activities across the licences. The programme is expected to include extensive drilling, with significant work scheduled to be completed by the end of 2026.

Galileo expects the disposal to generate a profit and strengthen its financial position, while simultaneously allowing the company to focus on developing its existing portfolio in southern Africa.

Strategic Focus on Core Assets

The sale represents another step in Galileo’s approach of monetising non-core assets and redeploying capital into projects where it sees the greatest opportunity for value creation. Management believes the transaction provides immediate funding while preserving the possibility of substantial future returns linked to exploration success.

Market Considerations

The company’s outlook continues to be influenced by a lack of revenue, recurring operating losses and negative free cash flow, although its debt-free balance sheet provides an important offsetting strength. Technical indicators are generally neutral to modestly positive, while valuation remains difficult to assess given negative earnings and the absence of a dividend yield.

More About Galileo Resources

Galileo Resources is a mineral exploration and development company focused primarily on copper and other base metals in southern Africa. The group’s main activities are centred on exploration projects in Zambia and Zimbabwe, while it continues to evaluate opportunities to unlock value from non-core assets and redirect capital towards priority growth areas.

Poolbeg Pharma (LSE:POLB) has received a decision to grant a European patent covering the use of POLB 001 for the prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The patent protection extends to p38 MAPK inhibitors across key member states of the European Patent Organisation, representing a significant addition to the company’s intellectual property portfolio.

The development follows recent patent grants in Australia and Canada and further strengthens Poolbeg’s protection in major pharmaceutical markets worldwide.

Intellectual Property Position Strengthened

The newly granted patent enhances the company’s competitive position as it progresses POLB 001 through clinical development. Poolbeg believes the expanded intellectual property coverage increases the strategic and commercial value of the programme while providing greater protection for future development and licensing opportunities.

Management has highlighted the importance of a robust patent estate in supporting the long-term potential of POLB 001, particularly as interest in therapies designed to improve the safety of cancer immunotherapies continues to grow.

Clinical Milestones on the Horizon

Poolbeg is continuing to advance POLB 001 through its development pathway, with interim data from the ongoing TOPICAL trial expected later this summer. The company believes the combination of clinical progress and strengthened patent protection enhances the attractiveness of the asset to potential pharmaceutical partners.

The upcoming trial results are expected to provide further insight into the potential role of POLB 001 in reducing the risk of Cytokine Release Syndrome, a serious complication associated with certain cancer immunotherapy treatments.

Market Considerations

The company’s outlook continues to be influenced by its pre-revenue status, ongoing losses, cash burn and equity erosion. However, recent regulatory and clinical progress, together with upcoming data readouts, provide potential catalysts for investor interest. Technical indicators suggest the shares remain in a strong upward trend, although overbought conditions may increase the risk of near-term volatility. Valuation metrics remain constrained by the absence of earnings and dividend payments.

More About Poolbeg Pharma Ltd.

Poolbeg Pharma is a clinical-stage biopharmaceutical company focused on advancing therapies that improve outcomes in cancer immunotherapy. Its lead programme, POLB 001, is being developed to prevent Cytokine Release Syndrome, with the goal of making cancer immunotherapies safer and more accessible. The company is also developing an oral GLP-1 treatment for obesity, targeting a large and rapidly growing global market.

Gana Media Group (LSE:GANA) has completed a £750,000 fundraising before expenses through a placing and subscription of 375,000,000 new ordinary shares at 0.2 pence per share, representing a slight premium to the company’s recent AIM closing price. The fundraising also includes warrants exercisable at 0.4 pence, with directors participating in the transaction.

Following the issue of the new shares, Gana’s total issued share capital will increase to approximately 18.1 billion shares. Outstanding warrants and options will represent around 16% of the enlarged share capital.

Capital Targeted at Estadio Gana Growth Initiatives

The proceeds will be used to accelerate growth plans centred on Estadio Gana, the company’s online casino and sportsbook platform in Mexico. Management reported strong increases in both customer registrations and wagering activity during the second quarter, reinforcing confidence in the platform’s growth trajectory.

The company believes the additional funding will allow it to build on this momentum and strengthen its position ahead of the upcoming World Cup period. Management expects the investment to support further market penetration and enhance the brand’s presence within the expanding Latin American online betting and entertainment sector.

Focus on Scaling Operations

Gana sees the fundraising as an opportunity to invest in customer acquisition, platform development and broader commercial initiatives as it seeks to expand its footprint in one of the region’s fastest-growing digital wagering markets.

While recent operational trends have been encouraging, the company continues to focus on converting growth into sustainable financial performance as it scales its sportsbook and gaming operations.

Market Considerations

The company’s outlook remains constrained by continuing operating losses and negative free cash flow, despite a recovery in revenue during FY2025 and strong gross margins. Technical indicators continue to reflect a prolonged downward trend, with the share price trading below key moving averages and momentum signals remaining weak. Valuation metrics also provide limited support due to the absence of positive earnings and dividend income.

More About Gana Media Group

Gana Media Group is an AIM-listed content and data intelligence business focused on building an integrated sports, media and entertainment platform across Latin America. The company’s portfolio includes Estadio Gana, a licensed Mexican online casino and sportsbook designed to capture growing demand for digital betting and gaming services in the region.

Pri0r1ty Intelligence Group (LSE:PR1) has secured a 12-month agreement between its Halfspace division and the Sport & Recreation Alliance, under which Halfspace will serve as the organisation’s official AI partner. The partnership includes the launch of the SportTower.ai platform, which will be made available to almost 300 sports and recreation bodies across the UK, representing an estimated 15,000 users.

The agreement marks the first commercial deployment of SportTower.ai, providing Alliance members with access to Pri0r1ty’s artificial intelligence and data analytics capabilities. The platform is designed to help organisations strengthen community engagement, improve decision-making and identify new revenue opportunities. For Pri0r1ty, the partnership also establishes a scalable framework that can be replicated across other industries and strategic alliances.

AI Platform Designed for Sector-Wide Adoption

Developed using Pri0r1ty’s existing AI technology stack, SportTower.ai includes a range of tools such as Advisor, Fan Sonar, Vox and Compass ID. The platform also delivers industry trend analysis and enables organisations to build AI-driven systems using their own datasets within a GDPR-compliant environment.

Halfspace expects to generate recurring revenues as Alliance members adopt and subscribe to elements of the product suite. The company believes the partnership strengthens its position within the sports sector while creating opportunities to expand its reach through additional collaborations and deployments in the months ahead.

Expanding Presence Across Key Markets

The launch represents another step in Pri0r1ty’s strategy to broaden the adoption of its AI solutions and data-driven services. By working with a large network of sports and recreation organisations, the company aims to demonstrate the practical benefits of its technology while establishing a repeatable model for future growth.

More About Pri0r1ty Intelligence Group PLC

Pri0r1ty Intelligence Group PLC is a UK-listed provider of data, artificial intelligence and marketing services focused on helping organisations improve engagement and growth. The business operates through three divisions: Halfspace, which specialises in data-led marketing and growth solutions for the sports industry; Pri0r1ty, an AI software and consultancy platform serving SMEs; and Metr1c, which delivers brand partnership and growth solutions for the entertainment sector.